Details:
The financing will be used to fund the Phase 2, Part B KALAHARI trial evaluating Oxurion’s THR-149, a bicyclic peptide that selectively inhibits human plasma kallikrein, for treating the up to 50% of patients with diabetic macular edema (DME).
Lead Product(s): THR-149
Therapeutic Area: Endocrinology Product Name: THR-149
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Atlas Special Opportunities
Deal Size: $22.8 million Upfront Cash: Undisclosed
Deal Type: Financing April 27, 2023
Details:
IMCY-0098, a synthetic peptide based on insulin, is designed to halt the progression of diabetes by stopping the body’s immune system from attacking beta cells. With early intervention, the pancreas’ ability to produce insulin may be preserved to manage the disease.
Lead Product(s): IMCY-0098
Therapeutic Area: Endocrinology Product Name: IMCY-0098
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
Positive interim biomarker Phase 2 IMPACT Type 1 Diabetes Study data support specific immune signature induced by Imotope (IMCY-0098) and effect on potentially pathogenic T cells.
Lead Product(s): IMCY-0098
Therapeutic Area: Endocrinology Product Name: Imotope
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2022